Edwards Lifesciences Corporation $EW Shares Bought by Jefferies Financial Group Inc.

Jefferies Financial Group Inc. raised its holdings in shares of Edwards Lifesciences Corporation (NYSE:EW) by 649.1% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 296,800 shares of the medical research company’s stock after buying an additional 257,180 shares during the quarter. Jefferies Financial Group Inc.’s holdings in Edwards Lifesciences were worth $25,620,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also added to or reduced their stakes in the company. BlackRock Inc. purchased a new stake in shares of Edwards Lifesciences in the 2nd quarter valued at about $5,318,092,000. Bank of New York Mellon Corp bought a new stake in shares of Edwards Lifesciences during the 2nd quarter valued at about $1,274,082,000. Bank of America Corp DE bought a new stake in shares of Edwards Lifesciences during the 2nd quarter valued at about $605,397,000. Deutsche Bank AG bought a new stake in shares of Edwards Lifesciences during the 2nd quarter valued at about $516,552,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in shares of Edwards Lifesciences by 0.6% during the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 5,488,643 shares of the medical research company’s stock worth $496,503,000 after purchasing an additional 30,495 shares in the last quarter. 79.46% of the stock is currently owned by institutional investors.

Insider Transactions at Edwards Lifesciences

In related news, VP Annette Brüls sold 2,644 shares of the firm’s stock in a transaction dated Friday, August 28th. The stock was sold at an average price of $89.98, for a total transaction of $237,907.12. Following the transaction, the vice president directly owned 17,984 shares of the company’s stock, valued at approximately $1,618,200.32. This trade represents a 12.82% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, SVP Andrew M. Dahl sold 544 shares of the firm’s stock in a transaction dated Monday, August 31st. The shares were sold at an average price of $91.06, for a total value of $49,536.64. Following the transaction, the senior vice president directly owned 14,868 shares in the company, valued at approximately $1,353,880.08. This represents a 3.53% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 53,945 shares of company stock valued at $5,498,306 over the last 90 days. Company insiders own 0.31% of the company’s stock.

Edwards Lifesciences Stock Up 1.9%

EW opened at $105.98 on Thursday. The business’s fifty day simple moving average is $89.77 and its 200 day simple moving average is $86.09. Edwards Lifesciences Corporation has a 52 week low of $74.66 and a 52 week high of $106.05. The company has a quick ratio of 3.86, a current ratio of 4.60 and a debt-to-equity ratio of 0.05. The stock has a market cap of $60.94 billion, a PE ratio of 59.87, a P/E/G ratio of 2.78 and a beta of 0.85.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Wednesday, November 4th. The medical research company reported $0.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.74 by $0.06. Edwards Lifesciences had a return on equity of 16.06% and a net margin of 15.30%. The firm had revenue of $1.72 billion during the quarter, compared to analyst estimates of $1.68 billion. During the same quarter in the previous year, the company posted $0.67 earnings per share. The company’s revenue was up 10.5% compared to the same quarter last year. As a group, research analysts expect that Edwards Lifesciences Corporation will post 3.01 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

EW has been the topic of several research analyst reports. Mizuho set a $120.00 price objective on shares of Edwards Lifesciences in a research report on Thursday, November 5th. Rothschild & Co Redburn raised their target price on shares of Edwards Lifesciences from $99.00 to $102.00 and gave the company a “buy” rating in a research note on Monday, July 27th. Royal Bank Of Canada lifted their target price on shares of Edwards Lifesciences from $110.00 to $115.00 and gave the company an “outperform” rating in a research report on Thursday, November 5th. TD Cowen lifted their target price on shares of Edwards Lifesciences from $117.00 to $121.00 and gave the company a “buy” rating in a research report on Wednesday. Finally, Citigroup boosted their price target on shares of Edwards Lifesciences from $110.00 to $117.00 and gave the stock a “buy” rating in a research note on Thursday, November 5th. Twenty-three research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $109.56.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on therapies for structural heart disease and critical care. Its products include transcatheter and surgical heart valves, as well as technologies used to monitor patients during intensive care and surgery. The company traces its origins to 1958, when engineer Lowell Edwards and surgeon Albert Starr began developing an artificial heart valve. Their work led to the Starr-Edwards valve, introduced in 1960. Edwards Lifesciences is headquartered in Irvine, California, and serves clinicians and patients around the world.